)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AB SCIENCE
AB SCIENCE (AB) investor relations material
AB SCIENCE H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary14 Oct, 2026
Executive summary
H1 2026 revenue was €498k; operating loss widened to €10.4m and net loss to €9.0m, mainly reflecting a €6.5m CIR provision.
Clinical priorities shifted to AB8939 in AML and masitinib in ALS, with trial restarts planned for 2027 after quality-system work.
April–August private placements raised €19.7m; cash after the August raise was reported at ~€23m.
Financial highlights
Net sales were €498k in H1 2026 versus €515k in H1 2025, entirely from veterinary Masivet.
Operating loss was €10.4m versus €2.7m; net loss was €9.0m versus €5.2m, with the deterioration primarily reflecting the €6.5m CIR provision and higher employment-litigation provisions.
Net financial result improved to a €1.4m gain from a €2.4m loss, including a €2.0m ROMANE advance remeasurement benefit.
Cash and cash equivalents were €9.0m at June 30; shareholders’ equity was negative €22.5m.
Outlook and guidance
Cash needs were estimated to be covered through FY2026 and 2027, supported by July and August equity raises, an expected €1.1m CIR payment and deferred debt maturities; trailing 12-month cash burn averaged €9m/year.
A new quality-management system and external audit were planned by year-end 2026; AB8939 Phase 1 was targeted to resume in Q1 2027 and masitinib ALS Phase 3 in Q4 2027.
The AP-HP-sponsored masitinib sickle-cell study was expected to begin in early 2027 and was described as unaffected by inspection-related delays.
Strategic priorities include AB8939 in AML, masitinib in ALS, asset review, potential partnerships and veterinary sales development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AB SCIENCE
- Authorized Phase 3 programs advance masitinib across ALS, MS and Alzheimer’s disease.AB
Corporate presentation - Net loss fell 80% year-over-year as clinical focus narrowed to ALS and AML, with improved cash and financing.ABH2 2025
- AB8939 plus venetoclax showed 100% response in high-risk AML with no hematological toxicity.ABStatus Update
- Operating loss fell 24% but net loss rose; €6.3M raised for clinical and patent milestones.ABH1 2025
- AB8939 shows strong efficacy in refractory and MECOM AML, with Phase II trials and funding secured.ABStatus Update
- Net loss and operating deficit dropped, cash position improved, but regulatory risks persist.ABH1 2024
- Operating loss halved and cash bolstered as clinical pipeline advances and IP portfolio grows.ABH2 2024
- Masitinib advances in neurodegenerative diseases with new trials and a January 2025 update webcast.ABStatus Update
Next AB SCIENCE earnings date
H2 202630 Apr, 2027
AB SCIENCE
Next AB SCIENCE earnings date
H2 202630 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AB Science is a biotechnology company specializing in the research, development, and commercialization of targeted therapies for serious diseases. The company focuses on small molecule drugs designed to address conditions in oncology, neurodegenerative disorders, and inflammatory diseases. The company is headquartered in Paris, France, and its shares are listed on the Euronext Paris.